Is ALLO or ALMS more undervalued in 2026?

CirclFi compares Allogene Therapeutics, Inc. (ALLO) and Alumis Inc. (ALMS) using 13 institutional-grade valuation models. ALLO has a Quality of Company score of 4.7/10 while ALMS scores 4.6/10.

Which is a better buy — ALLO or ALMS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ALLO and ALMS valuations compare?

ALLO at $2.25 and ALMS at $21.40 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ALLO vs ALMS Valuation Comparison 2026 — Intrinsic Value Analysis

ALLO

Biotechnology

Allogene Therapeutics, Inc.

Quality

4.7

out of 10

Value Trap

WARN

Price

$2.25

Last close

Models

9/13

Active

ALMS

Biotechnology

Alumis Inc.

Quality

4.6

out of 10

Value Trap

SAFE

Price

$21.40

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	ALLO Fair Value	ALLO Upside	ALMS Fair Value	ALMS Upside
Bayesian DCF	Intrinsic	$0.56	-75.3%	$4.81	-77.5%
Earnings Power Value	Intrinsic	—	—	$11.35	-54.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.05	-97.9%	$0.24	-98.9%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ALLO vs ALMS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ALLO vs ALMS — Which Stock Is More Undervalued?

ALLO scores higher with a 4.7/10 quality rating vs ALMS's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Allogene Therapeutics, Inc. (ALLO) and Alumis Inc. (ALMS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ALLO currently trades at $2.25 with a QOC of 4.7/10, while ALMS trades at $21.40 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).